Chinese company classified under health care/biotechnology; specific business segments not established from available knowledge.
Chinese company classified under health care/biotechnology; specific business segments not established from available knowledge.
Moat: none
Headquarters: China · Employees: 2,755
Size Pacific Shuanglin Bio-pharmacy (000403.SZ) is a China Health Care company (Biotechnology) with a market value of $1.24B, the 1799th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.89 on 18 Nov 2026.
Performance Over six months the shares fell 20.6%, against -20.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 19 in its peer set.
Growth Revenue grew 1.5% over the last twelve months (peer median +15.3%); the operating margin is 9.7% (peer median -295.1%).
Valuation It trades at 26.5× forward earnings against a peer median of 41.3× (3rd cheapest of 7).
Capital Return on invested capital runs 1.6 points below its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.42B | CN¥2.62B | CN¥2.64B | CN¥2.32B | CN¥2.39B |
| Revenue growth | — | -1% | +14% | -3% | — |
| Gross profit | CN¥895M | CN¥1.04B | CN¥1.26B | CN¥1.15B | CN¥1.20B |
| EBITDA | n/a | CN¥715M | CN¥929M | CN¥781M | CN¥716M |
| Net income | CN¥212M | CN¥419M | CN¥745M | CN¥612M | CN¥587M |
| Free cash flow | -CN¥164M | -CN¥478M | -CN¥109M | CN¥379M | CN¥190M |
| Capital expenditure | CN¥226M | CN¥333M | CN¥521M | CN¥377M | CN¥379M |
| Total debt | CN¥1.06B | CN¥829M | CN¥672M | CN¥503M | CN¥407M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000403.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.5% | -13.4% | 8th highest of 21 |
| 6-month return | -20.6% | -20.3% | 9th lowest of 19 |
| Distance from 52-week high | -45.9% | -49.0% | 9th highest of 21 |
| Revenue growth (TTM) | +1.5% | +15.3% | 7th lowest of 15 |
| Operating margin | 9.7% | -295.1% | 3rd highest of 16 |
| Forward P/E | 26.5× | 41.3× | 3rd cheapest of 7 |
| ROIC minus cost of capital | -1.6 pp | -8.7 pp | 3rd highest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 26.5× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 38.6× | 33.2% | -13.1% |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 44.0× | 6.6% | -7.0% |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 25.6× | 15.3% | +9.9% |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | n/a | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 134.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.15B | n/a | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.15B | -25% | n/a | n/a | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 60.5× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% | +25.6% |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | n/a | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |